Nicole Longo Nicole is director of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Recent Posts
Fact Check: How hospitals continue to drive health care spending
By Nicole Longo | August 21, 2019
There is a lot of talk about health care costs in the United States that is mostly centered on prescription medicine spending, overlooking the largest share of U.S. health care spending – hospital...
Read More
340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients
By Nicole Longo | August 20, 2019
Congress created the 340B program to help safety-net providers, like federally-funded safety net clinics, access discounts on prescription medicines for vulnerable or uninsured patients....
Read More
New analysis: Government intervention in Part B threatens patient access to medicines
By Nicole Longo | August 19, 2019
A new analysis from Avalere looked at how access to medicines in Part B may be impacted if the government only covered a certain list of medicines, an approach known as applying a national...
Read More
Three things to know about the Part D GAO report
By Nicole Longo | August 16, 2019
The Government Accountability Office (GAO) recently released a new report looking at Medicare Part D and the role of Pharmacy Benefit Managers (PBMs) in the program. While the report provides a...
Read More
What they’re saying: Safety is top concern for recent drug importation proposal
By Nicole Longo | August 8, 2019
Last week, the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) released their “Safe Importation Action Plan,” which would allow importation of...
Read More
No matter how you structure it, government arbitration is wrong for Medicare drug coverage
By Nicole Longo | June 27, 2019
Despite concerns from a broad group of stakeholders, some in Washington continue to push for imposing government arbitration on Medicare drug coverage to set the price of a medicine....
Read More
By the numbers: A look at the Part B International Pricing Index Model
By Nicole Longo | June 6, 2019
Mounting research continues to point to how international reference pricing schemes, like the Department of Health and Human Services’ (HHS) International Pricing Index (IPI) Model, could result...
Read More
Fresh data show, yet again, 340B is growing while charity care dwindles at many 340B hospitals
By Nicole Longo | May 16, 2019
There has been broad acknowledgement in Congress and by the Administration, as well as by patient groups and some hospitals, that the 340B program is not working as Congress intended. Yet little...
Read More
Fact Check: How the Part B International Pricing Index Model replaces market competition with government-set prices
By Nicole Longo | May 3, 2019
One of the most common misconceptions about the administration’s proposed Part B International Pricing Index (IPI) Model is that it would improve competition in Medicare. However, mounting...
Read More
340B continues to drive shift in site of care for physician-administered medicines to more expensive hospital settings
By Nicole Longo | April 5, 2019
Is 340B benefiting the vulnerable, uninsured patients it was designed to help? Evidence continues to show otherwise. An updated analysis from Berkeley Research Group (BRG) is the latest to build...
Read More
Medicare Monday (100)
340B Spotlight (42)
Cost & Consequence (0)
